The approval of the first-in-class drug comes from the phase 1/2 AUGMENT-101 study, in which treatment with Revuforj resulted in 21% of patients going into complete remission (CR) or complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback